Drugs
Viragen, Inc. has entered into a 10-year license agreement with Kuhnil Pharm Co. Ltd. to distribute its multi-subtype, natural human alpha interferon, Multiferon, in South Korea. Under the agreement, Kuhnil Pharm will provide exclusive marketing rights to the drug in exchange for a small up-front license fee. The South Korean
Drugs
Avigen, a biopharmaceutical company, has reached an agreement to sell its AAV gene therapy assets to Genzyme Corp. for $12 million upfront, with additional milestone payments and royalty payments on developed products. The assets include all rights to an extensive patent estate and Avigen's Parkinson's disease
Drugs
Researchers from Japan, the Netherlands, and South Korea have made significant contributions to the field of gastroenterology, shedding light on the complexities of colorectal cancer metastasis. The studies investigated various molecular mechanisms and therapeutic strategies to improve treatment outcomes for patients with liver metastases. The findings of these studies have
Drugs
Gemin X Biotechnologies, Inc.'s GX15-070, a first-in-class targeted cancer treatment, has shown significant promise in preclinical studies against multiple types of blood cancers, including mantle cell lymphoma, multiple myeloma, acute myeloid leukemia, and chronic lymphocytic leukemia. The data, presented at the American Society of Hematology's 47th
Drugs
Piramed Limited, a privately-owned UK biotechnology company, has announced a research and development collaboration with Genentech, Inc., a US biotechnology company, to develop a new class of cancer drugs targeting a key intracellular enzyme involved in a broad range of cancers. This partnership has the potential to yield significant returns
Drugs
A novel gene transfer strategy has been developed that combines promoter and transgene activities to improve tumor cell inhibition. Researchers at the University of Sao Paulo, led by B.E. Strauss, have shown that this approach can lead to more robust expression of the transgene and more effective inhibition of
Drugs
The Food and Drug Administration has granted conditional approval to Vivitrol, a much-anticipated drug made by Alkermes Inc. that targets alcoholism. The medication, which is a once-a-month injection of naltrexone, has shown promise in reducing heavy drinking in patients undergoing counseling. While the FDA has requested additional scientific data and
Drugs
Sangamo BioSciences, Inc. has completed subject enrollment and treatment in its phase I study of SB-509, a novel ZFP therapeutic designed to treat diabetic neuropathy by upregulating the expression of vascular endothelial growth factor (VEGF). The study, which evaluated the safety of SB-509 in diabetics with mild to moderate diabetic
Drugs
Scientists at the University of North Carolina at Chapel Hill have identified a molecule called Ack1 that plays a significant role in the aggressive growth of prostate cancer. Ack1, a member of the growth-promoting tyrosine kinase gene family, stimulates tumor formation by signaling prostate cells to eliminate a tumor-suppressor protein.
Drugs
Artemis Pharmaceuticals GmbH and the Spanish biotechnology company Center for Applied Molecular Research Salamanca (Cibasa) have announced a worldwide marketing agreement to collaborate on marketing Cibasa's Oncostem technology. This technology is based on cancer stem cell (CSC) research and will be used to discover and develop novel anticancer
Drugs
Researchers led by Kelly Hunt, MD, have published preclinical data demonstrating that INGN 241 works synergistically with celecoxib to inhibit the growth and increase apoptosis of breast cancer cells. The study, published in the medical journal Surgery, showed that the combination of INGN 241 and celecoxib resulted in greater than
Drugs
Neuroblastoma is a complex and often unpredictable childhood cancer that affects the peripheral nervous system. A recent study by the Children's Oncology Group, published in the New England Journal of Medicine, identifies genetic defects on chromosomes 1 and 11 as significant risk factors for high-risk neuroblastoma. The research,
